CI 1.25-4.39; p < 0.01). After multivariate adjustment and stratification by CKD stage, the mortality risk remained significant in ESRD patients receiving warfarin (HR 6.62 with 95% CI 2.56-17.16; p < 0.001). Furthermore, adjusted rates of significant bleeding (incident rate ratio, IRR 3.57 with 95% CI 1.51-8.45; p < 0.01) and myocardial infarction (IRR 4.20 with 95% CI 1.78-9.91; p < 0.01) were higher among warfarin users. No differences in rates of ischemic or hemorrhagic strokes were found between the 2 groups. Conclusions: Warfarin use was associated with several-fold higher risk of death, bleeding, and myocardial infarction in dialysis patients. If additional studies suggest similar associations, the use of warfarin in dialysis patients warrants immediate reconsideration.
The role of oral anticoagulation in the treatment and prophylaxis of thromboembolism in the CKD population is complex [8] . While the prevalence of atrial fibrillation, deep-vein thrombosis, and pulmonary embolism is high in CKD/ESRD patients [9] [10] [11] [12] , the risk of bleeding and vascular calcification is simultaneously increased in this cohort [7, [13] [14] [15] [16] . To our knowledge, no randomized, prospective trials have been done to evaluate the net clinical benefit and safety of warfarin treatment in advanced CKD and ESRD, and only a small number of observational studies have compared the survival and bleeding outcomes associated with warfarin use among ESRD patients [17] [18] [19] [20] . Retrospective studies that analyzed warfarin use and outcomes in CKD/ESRD patients have largely focused on atrial fibrillation, with conflicting findings [16, [21] [22] [23] [24] [25] ] as compared to the general population where warfarin anticoagulation reduces stroke risk by 64% in the setting of atrial fibrillation [26] . Three large metaanalyses in CKD patients with atrial fibrillation were published in the past year, which included data on >30,000 hemodialysis patients. Tan et al. [27] reported an association between warfarin therapy with increased stroke and bleeding events, while the studies by Dahal's group and van der Meersch et al. [28] reported increased bleeding but no effect on stroke or mortality outcomes in hemodialysis patients [24] . In recent years, warfarin use has also been associated with increased prevalence and progression of vascular calcification in hemodialysis patients [20, 29] . Despite the limited and conflicting evidence for optimal management of long-term anticoagulation in the setting of reduced renal function, data from single-center studies indicate that warfarin is prescribed in 8.3-25% of ESRD patients [18, 26] .
Given the current paucity of data on the subject, there is a need to better determine the effects of warfarin use on cardiovascular events and all-cause mortality in this challenging population. The objective of this study was to investigate the survival and cardio vascular outcomes associated with incident warfarin use in a population of stages 3-5 CKD and ESRD patients with various indications for antico agulation (including vascular thrombosis, atrial fibrillation, pulmonary embolism, and hypercoagulable states) at the University of California, Irvine Medical Center.
Methods

Patient Population
In this observational retrospective study, we identified patients ≥ 18 years of age with stages 3-5 CKD and ESRD who were initiated on warfarin between January 1, 2011 and December 31, 2012 at the University of California-Irvine Medical Center (Orange, CA, USA) using the University of California Research eXchange (UC Rex) Data Explorer. Stages 3-5 CKD and ERSD patients were identified in UC Rex using their respective international classification of disease-9 codes [30, 31] . Exclusion criteria included patients with less than one month follow-up, lack of documentation on warfarin treatment start date, any documented warfarin use prior to CKD or ESRD diagnosis, or any documentation of warfarin use prior to start of follow-up for at least one year. The indications for anticoagulation included atrial fibrillation, pulmonary embolism and infarction, other venous embolism and thrombosis, hypercoagulable states, transient cerebral ischemia, heart valve replacement, old myocardial infarction or chronic ischemic heart disease, and other indications (arterial embolism/stenosis, arterial pseudoaneurysm, peripheral vascular disease, ventricular thrombosis).
A matched cohort of CKD/ESRD patients who were not warfarin-treated, as defined by the absence of warfarin use for at least one year prior to follow-up until end of follow-up, but had indications for anticoagulation, was used as a comparison group. Matching criteria included (1) gender, (2) age difference <5 years, and (3) indication for anticoagulation (identified by their respective international classification of disease-9 codes).
Data Collection and Clinical Characteristics
All data were recorded and exported using an Electronic Data Capture instrument designed with the Research Electronic Data Capture (REDCap Version 6.14.2) online software. The study protocol was approved by the University of California, Irvine Institutional Review Board.
Information on patient demographics, CKD stage, warfarin indications and contraindications, medication use, and comorbidities was obtained from chart review of the first admission or clinic visit from January 1, 2011 to December 31, 2012. Chart review was done of all available clinic notes and hospital notes up to the study end-date of October 10, 2016, to collect data on hospitalizations and mortality.
Outcome Definitions
The primary end-point of the study was all-cause death. Secondary end-points include the following: significant bleeding, myocardial infarction, heart failure, ischemic stroke, hemorrhagic stroke, and a composite outcome of cardiovascular events (combined myocardial infarction, heart failure, and ischemic stroke).
Myocardial infarction was defined as a documented diagnosis consistent with symptoms of coronary ischemia with sudden changes on electrocardiogram and/or rise in cardiac biomarker enzymes. Heart failure was defined as a documented diagnosis consistent with pulmonary congestion on radiographic imaging and clinical hypoxemia requiring admission. Ischemic and hemorrhagic stroke were defined as documented diagnoses consistent with sudden neurologic change with positive findings on neuroimaging suggestive of infarction and intraparenchymal/subarachnoid hemorrhage, respectively. Significant bleeding was defined as bleeding that required transfusion, hospital admission, in-hospital workup, or bleeding causing anemia.
Statistical Analyses
All data analyses were performed using the STATA software 251 while continuous variables were expressed in mean ± SD or median with interquartile range according to parametric distribution. Differences between the group's baseline and outcome variables were tested with Pearson's χ 2 test for categorical variables, and Student's t test for continuous variables (age). For group size less than 5, Fisher's exact test was used for categorical variables. Statistical significance was defined as a p value less than 0.05 with 2-sided testing. Survival and time-to-event curves were plotted using the Kaplan-Meier method. All analyses were conducted using unadjusted data and 3 adjustment models: 1-age and gender; 2-diabetes; 3-age, gender, use of antiplatelet agents (aspirin, clopidogrel) and preexisting diabetes, hypertension, myocardial infarction/ congestive heart failure and stroke. The association between exposure and outcome was analyzed using Cox proportional hazard regression for time-to-event data, and Poisson regression for event rates. The log-rank test was performed for equality of survivor functions. Within the multivariate adjusted model 3, analyses were tested by strata of CKD 3-5 vs. ESRD and tested for interaction using the Wald test. Hazard ratios (HRs) or incident rate ratios (IRR) are reported along with 95% confidence intervals (CIs).
Results
We identified 59 patients who were initiated on warfarin therapy between January 1, 2011 to December 31, 2012, and 144 matched patients with CKD and ESRD who had indications for anticoagulation therapy but did not receive warfarin treatment. Baseline characteristics of the no-warfarin and warfarin-treated groups are shown in Table 1 . There was no statistically significant difference between the 2 groups in terms of mean age (60 ± 15 vs. 60 ± 17; p = 0.947), proportion of females (45 vs. 49%; p = 0.63), and presence of diabetes, hypertension, myocardial infarction/heart failure, or stroke at the start of follow-up. Patients in both groups had similar baseline pharmacologic profiles; however, patients in the no-warfarin group were more likely to receive antiplatelet agents compared to those in the warfarin-treated group (66.7 vs. 50.8%; p = 0.035). There was a higher proportion of ESRD patients in the no-warfarin group (65.3 vs. 45.8%) with a corresponding lower proportion of stages 3-5 CKD patients in the no-warfarin group (34.7 vs. 54.2% in the warfarintreated group, p = 0.006). The mean follow-up period in the warfarin-treated group from start of treatment was 2.8 ± 1.6 years vs. 4.0 ± 1.5 years in the no-warfarin group from date of anticoagulation indication diagnosis ( p < 0.001). The median duration of warfarin treatment was 12 months (interquartile range 3.7-23.9 months).
Among warfarin users, 45.8% had an indication for anticoagulation due to venous embolism/thrombosis, 30.5% had atrial fibrillation, and 10.2% had pulmonary embolism compared to 56.9, 33.3, and 13.9% in the nowarfarin group, respectively ( p = 0.147, 0.696, 0.472). Three patients had 2 indications for anticoagulation. For the no-warfarin controls, the most common reasons for avoidance of warfarin therapy included recent surgery (36.8%), gastrointestinal ulcer or bleeding (21.5%), and increased hemorrhagic risk (16%); reason for warfarin non-initiation could not be determined from chart review in 34% of cases ( Table 1 ) . Of note, in the nonwarfarin group, 6 patients were on apixaban and one patient was on dabigatran during the study follow-up duration.
Online supplementary Table 1 (see www.karger. com/doi/10.1159/000481207) shows the cumulative incidence of primary and secondary outcomes from the start of follow-up until the study end-date of October 10, 2016. The differences in cumulative incidence of adverse outcomes were not statistically significant between the 2 groups. However, time-to-event and ratebased analyses showed significant differences in outcomes between the groups. Kaplan-Meier survival analysis demonstrated significantly lower survival in the warfarin-treated group as shown in Figure 1 (Log rank test = 0.0064). Results from Cox and Poisson regression analyses with univariate and multivariate adjustments are shown in Table 2 . With multivariate adjustment in model 3 stratified by CKD stages 3-5 vs. ESRD, there was a strong association between all-cause mortality and warfarin therapy in the ESRD strata (HR 6.62, 95% CI 2.56-17.16; p < 0.001). This mortality association was nonsignificant in the CKD stages 3-5 strata (HR 1.26, 95% CI 0.45-3.52; p = 0.661), p value for interaction = 0.035. We further analyzed the rate of adverse events that occurred within 90 days of death in both study groups. In the warfarin-treated group, 5 of the 16 deaths (31.3%) were preceded by a major adverse event within 90 days (4 myocardial infarction, 1 heart failure), vs. 3 of the 26 deaths (11.5%) in the no-warfarin cohort (1 myocardial infarction, 1 heart failure, 1 significant bleeding event).
In terms of secondary outcome measures, warfarin treatment was strongly associated with higher rates of myocardial infarction (IRR 3.28, 95% CI 1.45-7.43; p = 0.004) and significant bleeding (requiring transfusion or hospitalization, IRR 3.57, 95% CI 1.55-8.24; p = 0.003) in univariate analyses. No statistically significant association was found between warfarin use and rate of heart failure, ischemic stroke, or the composite outcome of cardiovascular events. Multivariate adjustment and stratification by CKD strata did not change the statistical relationships.
In this retrospective matched cohort study, incident warfarin therapy was associated with higher risk of allcause mortality in ESRD patients (p < 0.001). Secondary analysis showed a higher rate of bleeding and myocardial infarction with warfarin therapy in both stages 3-5 CKD and ESRD patients, while rates of stroke and heart failure were not significantly different.
Few studies have examined the impact of warfarin on all-cause mortality in the advanced CKD and ESRD population. In an observational study, Chan et al. [19] showed an increased morality in the hemodialysis population ( n = 2,369) associated with warfarin, aspirin, and clopidogrel use compared to nonusers ( n = 24,740) over 5 years of follow-up. In the same study, warfarin and clopidogrel users also had significantly higher risk for death or hospitalization from bleeding. In a systematic review, Elliott [18] concluded that warfarin use, when compared to subcutaneous heparin or no warfarin use, is associated with a higher bleeding risk in hemodialysis patients. The present study is consistent with these findings, as warfarin was associated with higher risk of all-cause mortality in the ESRD group and trended toward a higher rate of bleeding in both the stages 3-5 CKD and ESRD strata. The higher rate of preceding adverse cardiovascular or bleeding events within 90 days of death (31.3% in the warfarin group vs. 11.5% in the non-warfarin controls) suggests that warfarin-related morbidity may impact mortality risk; however, this needs to be validated in larger cohorts.
Vitamin K is an essential factor for the carboxylation and activation of matrix G1a protein, a potent endogenous inhibitor of arterial calcification that is produced by vascular smooth muscle cells [32, 33] . Warfarin, a vitamin K antagonist, blocks the carboxylation of matrix G1a protein and thereby increases the risk of vascular calcification. In a study utilizing serial, annual mammogram data from 451 women on warfarin therapy, warfarin was associated with a 50% increase in breast arterial calcification compared to untreated women matched for age and diabetes mellitus; severity of calcification increased with duration of therapy [34] . Warfarin therapy has been associated with increased calcification of the coronary arteries, peripheral arteries, mitral valves, and aortic valves in cross-sectional, image-based studies primarily in patients with atrial fibrillation or valvular disease [32] . Notably, vascular calcification and arterial stiffness are more prevalent in CKD than in the general population, and have been shown to be inde- pendent prognostic markers of all-cause mortality and cardiovascular events in patients with stages 4-5 CKD and ESRD [35] [36] [37] .
To our knowledge, although numerous studies have examined outcomes in patients with atrial fibrillation, very few have evaluated the potential relationship between warfarin use and cardiovascular events in the CKD and ESRD population. Mac-Way et al. [29] reported vitamin K deficiency and accelerated aortic stiffness with warfarin use in 19 hemodialysis patients after a mean exposure of 29 months. Furthermore, the degree of vitamin K deficiency was found to be associated with a higher risk of mortality. In a multi-center cross sectional study, Fusaro et al. [20] similarly concluded that hemodialysis patients ( n = 387) on warfarin had higher odds of aortic and iliac calcifications and risk of all-cause mortality after 3 years of follow-up. Our present study found that warfarin-treated ESRD patients had higher risk of all-cause death, while warfarin therapy in both strata of stages 3-5 CKD and ESRD patients was associated with higher risk of myocardial infarction and no protective effects on ischemic stroke. The increased myocardial infarction risk may be explained (at least in part) by warfarin driving vascular calcification, with subsequent increased arterial stiffness and increased systolic blood pressure and reduced diastolic blood pressure. These changes compromise perfusion of the coronary arteries during diastole and promote left ventricular remodeling [38] . Calcific uremic arteriolopathy (formerly called calciphylaxis) is a rare but often fatal syndrome of calcification in cutaneous blood vessels leading to skin necrosis that occurs in 5% of ESRD patients. Approximately 50% of such patients with calciphylaxis are on warfarin [32] . In the present study, we observed one case of calciphylaxis in the warfarintreatment group, and none in the no-warfarin group. Taken together, the evidence suggests that warfarin-induced vitamin K dysfunction leads to arterial stiffness and explains, at least in part, the associations observed in the CKD/ESRD warfarin-treated cohort.
This study possesses several limitations. First, the study is vulnerable to underreporting and/or misclassification of diagnoses and medication use due to its retrospective, observational nature. Information that is inconsistently available such as smoking history, ethnicity, socioeconomic status, and baseline laboratory findings cannot be captured reliably from this database. The specific cause of death was not reported. Second, we do not have information regarding INR levels and warfarin dosage among patients in the warfarin-treated group. While we included only patients with incident, as opposed to prevalent, warfarin use to control for exposure duration, it is possible that some patients in this group had suboptimal or supratherapeutic levels during follow-up, which could be a potential confounding factor. Third, selection bias regarding treatment decisions may be present for patients who have a higher risk of thromboembolism at baseline, thereby exaggerating the risks of adverse outcomes in the treatment group. Some of these biases may not have been fully accounted for in our multivariate adjustment models, although we adjusted for all major comorbidities associated with CKD/ESRD as well as all components of the CHADS2 score [39] . In the no-warfarin group, the most commonly identified reasons for warfarin avoidance were related to bleeding tendency (recent surgery, gastrointestinal bleeding, preexisting hemorrhagic risk; Table 1 ); however, we did not note an omission bias (i.e., greater stroke or mortality rates in the notreatment cohort due to physicians placing a higher value on avoiding a bleed than on avoiding a stroke). Finally, generalizability of our results is limited, since our study was conducted in a single academic center. With a limited sample size, stratification of patients based on predictors of mortality such as the Charlson comorbidity index would not yield sufficient power to arrive at meaningful conclusions.
In the past decade, new oral anticoagulants (NOACs) have been released on the market that include the direct thrombin inhibitor dabigatran and factor Xa inhibitors such as apixaban and rivaroxaban. In the current nonwarfarin cohort, 7/144 patients were exposed to an NOAC during the follow-up period. The factor Xa inhibitors in particular are promising alternatives to warfarin for use in CKD patients, since these agents are predominantly metabolized by the hepatic (not renal) route and may have less off-target effects. Apixaban was recently approved by the Food and Drug Administration for use in ESRD patients [40] . However, randomized controlled clinical trials are needed to confirm the safety profile of oral factor Xa inhibitors in advanced CKD. There have been 4 large Phase III trials since 2009 comparing NOACs against warfarin in patients with atrial fibrillation, but all the studies excluded CKD stage 4/5 and ESRD patients [41] [42] [43] [44] .
In summary, we observed a higher risk of all-cause death and higher rate of bleeding in CKD/ESRD patients who were initiated in warfarin therapy. Of note, there was a higher baseline prevalence of cardiovascular risk factors including diabetes, hypertension, and history of myocardial infarction/heart failure in our study compared to rates reported in large-scale clinical and epidemiologic
